1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24249
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPavlidis, N.en
dc.contributor.authorHanauske, A. R.en
dc.contributor.authorGamucci, T.en
dc.contributor.authorSmyth, J.en
dc.contributor.authorLehnert, M.en
dc.contributor.authorte Velde, A.en
dc.contributor.authorLan, J.en
dc.contributor.authorVerweij, J.en
dc.date.accessioned2015-11-24T19:39:28Z-
dc.date.available2015-11-24T19:39:28Z-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24249-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subject*Antineoplastic Agents/adverse effects/therapeutic useen
dc.subject*Aziridines/adverse effects/therapeutic useen
dc.subjectCarcinoma, Non-Small-Cell Lung/*drug therapy/pathologyen
dc.subjectDose-Response Relationship, Drugen
dc.subjectDrug Administration Scheduleen
dc.subjectFemaleen
dc.subjectHumansen
dc.subject*Indolequinonesen
dc.subject*Indoles/adverse effects/therapeutic useen
dc.subjectInjections, Intravenousen
dc.subjectLung Neoplasms/*drug therapy/pathologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectSurvival Rateen
dc.subjectTreatment Outcomeen
dc.titleA randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG)en
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8839911-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1996-
heal.abstractIn a multicentre randomized trial of the EORTC-ECSG, we have treated 38 chemotherapy naive patients with advanced non-small-cell lung cancer (NSCLC) with EO9, a novel bio-reductive alkylating indoloquinone. The drug was given at two different dose schedules by a single bolus i.v. injection: arm A 12 mg/m2 weekly and arm B 22 mg/m2 every three weeks. All together 185 courses were administered (145 in arm A and 40 in arm B). The major toxicity was reversible proteinuria more frequently occurring in the three-weekly schedule (arm A 34.5% vs. arm B 62.5%). Creatinine elevation, fluid retention and pericardial or pleural effusion were also recorded in a limited number of patients. Other common toxicities more frequent in the three-weekly administration were asthenia (21% vs. 35% of cycles), nausea (15% vs. 27.5% of cycles) and vomiting (5% vs. 17.5% of cycles). Toxicities were mainly of grade I and II. No responses have been observed. Five patients (26%) on arm A and eight (53%) on arm B experienced stable disease. These doses and schedules of EO9 do not yield activity in NSCLC.en
heal.journalNameAnn Oncolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Pavlidis-1996-a randomized phase.pdf204.22 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons